Disease-Dependent Differences in Busulfan CL/F Expressed Relative to BW, BSA, or AIBW
| Busulfan CL/F Expressed Relative to: . | Disease (1) . | Disease (2) . | %, Mean Difference* . | P . |
|---|---|---|---|---|
| BW (mL/min/kg) | NHL | AML | −31.2 | .045 |
| NHL | CML | −36.0 | .007 | |
| BSA (mL/min/m2) | NHL | CML | −32.0 | .006 |
| AIBW (mL/min/kg) | NHL | BrCa | −31.1 | .017 |
| NHL | CML | −33.1 | .006 | |
| NHL | MM | −34.8 | .012 |
| Busulfan CL/F Expressed Relative to: . | Disease (1) . | Disease (2) . | %, Mean Difference* . | P . |
|---|---|---|---|---|
| BW (mL/min/kg) | NHL | AML | −31.2 | .045 |
| NHL | CML | −36.0 | .007 | |
| BSA (mL/min/m2) | NHL | CML | −32.0 | .006 |
| AIBW (mL/min/kg) | NHL | BrCa | −31.1 | .017 |
| NHL | CML | −33.1 | .006 | |
| NHL | MM | −34.8 | .012 |
Busulfan CL/F expressed relative to BW, AIBW, or BSA, relative to BW, BSA, or AIBW was compared among patients with AML (n = 60), BrCa (n = 55), CML (n = 73), myelodysplastic syndrome (n = 49), MM (n = 25), non-Hodgkin’s lymphoma (n = 10), and ovarian cancer (n = 7). Statistical comparisons were made using one-way ANOVA with the Bonferroni correction for multiple comparisons. Only the statistically significant results were listed in the table.